Triggers And Risk Factors to Develop a Reversible Cerebral Vasoconstriction Syndrome — TARDIS  

Reversible Cerebral Vasoconstriction Syndrome Clinical Trial

Official title: Identification of Reversible Cerebral Vasoconstriction Syndrome's Precipitating Factors. Triggers And Risk Factors to Develop a Reversible Cerebral Vasoconstriction Syndrome

Status Recruiting

Clinical Trial Summary

This study will be the first to evaluate the role played by potential precipitating factors and risk factors in Reversible Cerebral Vasoconstriction Syndrome (RCVS) through of prospective selection of carefully characterised patients and controls. The impact of these factors on the prognosis will be evaluated through a follow-up assessment of patients.

Our study will include the formation of a clinicoradiological database and a biobank (plasma, cerebro-spinal fluid, DNA) which will be the tools of a future large multicentre study on RCVS.

Clinical Trial Description

Introduction : Reversible Cerebral Vasoconstriction Syndrome (RCVS) combines headaches and segmental constriction of cerebral arteries that resolves within 3 months.

It is the most recurrent reason of cerebral arteriopathy in people under 70 and of thunderclap headache in absence of aneurysmal subarachnoid haemorrhage.

Objectives :

• Principal: identify RCVS's precipitating factors

• Secondary:

1. Determine if migraine, anxiety, depression are risk factors of RCVS.

2. Determine the role of precipitating factors and risk factors on the RCVS's prognosis in short, medium and long term.

3. Start a formation of a large clinicoradiological database and a biobank (plasma, cerebro-spinal fluid, DNA).

Methodology :

Monocentric analytic observational 'Case - Control' study with prospective inclusion of cases in a follow-up cohort.

This type of study is nevertheless considered interventional because we are collecting additional blood and CSF samples to constitute a biobank. ;

Related Conditions & MeSH terms

• Reversible Cerebral Vasoconstriction Syndrome
• Syndrome

• NCT number: NCT04179383
• Study type: Interventional
• Source: University Hospital, Montpellier
• Contact: Lucas CORTI
• Phone: 06.76.31.63.12
• Email: l-corti@chu-montpellier.fr
• Status: Recruiting
• Phase: N/A
• Start date: December 5, 2019
• Completion date: September 2024